Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
COLO-PREVENT
ISRCTN13526628Phase 3Recruiting
- Sponsor
- University of Leicester
- Start
- Sep 2022
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of aspirin, metformin and resveratrol in colonic polyp and colorectal cancer (CRC) (5 arms), sponsored by University of Leicester. Primary endpoint: Mean number of polyps per participant. Started Sep 2022; status: recruiting.
02
Drugs
aspirinmetforminresveratrol
03
Conditions
colonic polypcolorectal cancer (CRC)
Beyond the preview
Go deeper on ISRCTN13526628.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN13526628.